Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
I-MAB ( (IMAB) ) has issued an announcement.
I-Mab Biopharma has completed the divestiture of its China operations and is advancing its clinical strategy for accelerated growth with a focus on three active programs, including givastomig, uliledlimab, and ragistomig. The company is targeting significant market opportunities in the U.S., Europe, and Japan, with potential advancements in precision immuno-oncology therapeutics. Significant clinical data releases are anticipated in 2025 and 2026 that could impact its strategic positioning and stakeholder interests in the biopharmaceutical market.
More about I-MAB
I-Mab Biopharma is a company focused on precision immuno-oncology therapeutics. It operates in the biopharmaceutical industry, specializing in the development of monoclonal antibodies and bispecific antibodies targeting various forms of cancer. The company’s market focus includes treatments for gastric cancer, pancreatic ductal adenocarcinoma, and cholangiocarcinoma, among others.
YTD Price Performance: 15.38%
Average Trading Volume: 491,773
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $80.87M
Learn more about IMAB stock on TipRanks’ Stock Analysis page.
